Protein/Antibody drug discovery and development is the process of identifying new therapeutic antibodies to combat different diseases. These antibody therapeutics can become in a number of different formats, such as full length antibodies, bispecific antibodies, antibody fragments, and more. Conventional approaches for the discovery and pre-clinical development take two to three years, CD ComputaBio’s technologies, based on artificial intelligence (AI), machine learning (ML), allow shrinking this time to a few weeks.
Figure 1 Protein/Antibody Drug Development Overview
Artificial intelligence is capable of reducing high costs in drug research and development as it finds solutions faster and with precision. CD ComputaBio implements AI-driven solutions for the development of therapeutic antibodies, as bio-drugs are used in an increasing number of pathologies, including oncology. CD ComputaBio’s objective is to propose a software suite that creates a formal approach of antibody development, reducing the risks of failure and the duration of pre-clinical steps, as well as strengthening intellectual protection.
Tech Trends in Artificial Intelligence What's up, what's down, what lies ahead, only found in MedAI!